FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2132170452> ?p ?o ?g. }

• W2132170452 endingPage "1179" @default.
• W2132170452 startingPage "1171" @default.
• W2132170452 abstract "BackgroundFluticasone furoate/vilanterol (FF/VI) is an inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA), recently approved as once-daily maintenance therapy for COPD. We compared the lung function effects of FF/VI with those of twice-daily fluticasone propionate/salmeterol (FP/SAL).MethodsThree 12 week studies comparing FF/VI and FP/SAL were conducted. Patients aged ≥40 years with moderate-to-very severe COPD were randomized to receive double-blind, double-dummy FF/VI 100/25 mcg once-daily, or FP/SAL 250/50 mcg twice-daily for 12 weeks following a 2 week placebo run-in period. The primary endpoint of each study was change from baseline trough in 0–24 h weighted mean FEV1 (wmFEV1) on Day 84. Safety was also assessed.ResultsIn Study 1 (HZC113109) (intent-to-treat n: FF/VI = 260; FP/SAL = 259), the increase from baseline in 0–24 h wmFEV1 was significantly greater with FF/VI than FP/SAL (Δ80 mL, P < 0.001). In Study 2 (HZC112352) (intent-to-treat n: FF/VI = 259; FP/SAL = 252) and Study 3 (RLV116974) (intent-to-treat n: FF/VI = 412; FP/SAL = 416), the increase from baseline in 0–24 h wmFEV1 was not significantly greater with FF/VI than FP/SAL (Δ29 mL, P = 0.267; Δ25 mL, P = 0.137). The treatment difference was statistically but not clinically significant in a pooled analysis (Δ41 mL, P < 0.001). Pooled adverse events (FF/VI 27%; FP/SAL 28%) and serious adverse events (FF/VI 2%; FP/SAL 3%) were similar between treatments.ConclusionsOur data suggest that once-daily FF/VI 100/25 mcg provides FEV1 improvement in COPD that is at least comparable with that conferred by twice-daily FP/SAL 250/50 mcg, although interpretation is limited by differences in individual study outcomes. The safety profiles of FF/VI 100/25 mcg and FP/SAL 250/50 mcg are similar.Clinical trial registrationclinicaltrials.gov: NCT01323634; NCT01323621; NCT01706328. GlaxoSmithKline study codes: HZC113109; HZC112352; RLV116974." @default.
• W2132170452 created "2016-06-24" @default.
• W2132170452 creator A5015887122 @default.
• W2132170452 creator A5024393985 @default.
• W2132170452 creator A5024466535 @default.
• W2132170452 creator A5034691201 @default.
• W2132170452 creator A5045112331 @default.
• W2132170452 creator A5045141623 @default.
• W2132170452 creator A5079023447 @default.
• W2132170452 creator A5082568705 @default.
• W2132170452 creator A5082911997 @default.
• W2132170452 date "2014-08-01" @default.
• W2132170452 modified "2023-10-16" @default.
• W2132170452 title "Efficacy and safety of once-daily fluticasone furoate/vilanterol (100/25 mcg) versus twice-daily fluticasone propionate/salmeterol (250/50 mcg) in COPD patients" @default.
• W2132170452 cites W1999225686 @default.
• W2132170452 cites W2001104945 @default.
• W2132170452 cites W2003172053 @default.
• W2132170452 cites W2047617002 @default.
• W2132170452 cites W2074234735 @default.
• W2132170452 cites W2077456532 @default.
• W2132170452 cites W2088797046 @default.
• W2132170452 cites W2095049468 @default.
• W2132170452 cites W2095666112 @default.
• W2132170452 cites W2100738224 @default.
• W2132170452 cites W2105402505 @default.
• W2132170452 cites W2108678383 @default.
• W2132170452 cites W2113012210 @default.
• W2132170452 cites W2118866729 @default.
• W2132170452 cites W2127104182 @default.
• W2132170452 cites W2129633626 @default.
• W2132170452 cites W2130795051 @default.
• W2132170452 cites W2138833643 @default.
• W2132170452 cites W2142627051 @default.
• W2132170452 cites W2142724633 @default.
• W2132170452 cites W2144062478 @default.
• W2132170452 cites W2166432084 @default.
• W2132170452 doi "https://doi.org/10.1016/j.rmed.2014.05.008" @default.
• W2132170452 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24998880" @default.
• W2132170452 hasPublicationYear "2014" @default.
• W2132170452 type Work @default.
• W2132170452 sameAs 2132170452 @default.
• W2132170452 citedByCount "27" @default.
• W2132170452 countsByYear W21321704522014 @default.
• W2132170452 countsByYear W21321704522015 @default.
• W2132170452 countsByYear W21321704522016 @default.
• W2132170452 countsByYear W21321704522017 @default.
• W2132170452 countsByYear W21321704522018 @default.
• W2132170452 countsByYear W21321704522019 @default.
• W2132170452 countsByYear W21321704522020 @default.
• W2132170452 countsByYear W21321704522023 @default.
• W2132170452 crossrefType "journal-article" @default.
• W2132170452 hasAuthorship W2132170452A5015887122 @default.
• W2132170452 hasAuthorship W2132170452A5024393985 @default.
• W2132170452 hasAuthorship W2132170452A5024466535 @default.
• W2132170452 hasAuthorship W2132170452A5034691201 @default.
• W2132170452 hasAuthorship W2132170452A5045112331 @default.
• W2132170452 hasAuthorship W2132170452A5045141623 @default.
• W2132170452 hasAuthorship W2132170452A5079023447 @default.
• W2132170452 hasAuthorship W2132170452A5082568705 @default.
• W2132170452 hasAuthorship W2132170452A5082911997 @default.
• W2132170452 hasBestOaLocation W21321704521 @default.
• W2132170452 hasConcept C126322002 @default.
• W2132170452 hasConcept C142724271 @default.
• W2132170452 hasConcept C197934379 @default.
• W2132170452 hasConcept C204787440 @default.
• W2132170452 hasConcept C27081682 @default.
• W2132170452 hasConcept C2776719499 @default.
• W2132170452 hasConcept C2776780178 @default.
• W2132170452 hasConcept C2776804153 @default.
• W2132170452 hasConcept C2779028295 @default.
• W2132170452 hasConcept C71924100 @default.
• W2132170452 hasConcept C90924648 @default.
• W2132170452 hasConceptScore W2132170452C126322002 @default.
• W2132170452 hasConceptScore W2132170452C142724271 @default.
• W2132170452 hasConceptScore W2132170452C197934379 @default.
• W2132170452 hasConceptScore W2132170452C204787440 @default.
• W2132170452 hasConceptScore W2132170452C27081682 @default.
• W2132170452 hasConceptScore W2132170452C2776719499 @default.
• W2132170452 hasConceptScore W2132170452C2776780178 @default.
• W2132170452 hasConceptScore W2132170452C2776804153 @default.
• W2132170452 hasConceptScore W2132170452C2779028295 @default.
• W2132170452 hasConceptScore W2132170452C71924100 @default.
• W2132170452 hasConceptScore W2132170452C90924648 @default.
• W2132170452 hasFunder F4320307773 @default.
• W2132170452 hasIssue "8" @default.
• W2132170452 hasLocation W21321704521 @default.
• W2132170452 hasLocation W21321704522 @default.
• W2132170452 hasLocation W21321704523 @default.
• W2132170452 hasOpenAccess W2132170452 @default.
• W2132170452 hasPrimaryLocation W21321704521 @default.
• W2132170452 hasRelatedWork W1989275727 @default.
• W2132170452 hasRelatedWork W2014561368 @default.
• W2132170452 hasRelatedWork W2024276633 @default.
• W2132170452 hasRelatedWork W2038694240 @default.
• W2132170452 hasRelatedWork W2055941908 @default.
• W2132170452 hasRelatedWork W2143455753 @default.
• W2132170452 hasRelatedWork W2473479517 @default.
• W2132170452 hasRelatedWork W2514696388 @default.

• next